Ra Capital Management as of June 30, 2020
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 57 positions in its portfolio as reported in the June 2020 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Ascendis Pharma A S Sponsored Adr (ASND) | 14.2 | $727M | 4.9M | 147.90 | |
Forma Therapeutics Hldgs SHS | 8.2 | $419M | 9.0M | 46.49 | |
Novavax Com New (NVAX) | 7.7 | $397M | 4.8M | 83.35 | |
Chemocentryx | 5.4 | $278M | 4.8M | 57.54 | |
Tg Therapeutics (TGTX) | 4.9 | $249M | 13M | 19.48 | |
Vaxcyte (PCVX) | 3.4 | $174M | 5.5M | 31.61 | |
Axsome Therapeutics (AXSM) | 3.3 | $168M | 2.0M | 82.28 | |
Adverum Biotechnologies | 3.2 | $163M | 7.8M | 20.88 | |
Satsuma Pharmaceuticals Ord | 2.6 | $135M | 4.7M | 28.76 | |
Adaptimmune Therapeutics Sponds Adr (ADAP) | 2.5 | $131M | 13M | 10.01 | |
Macrogenics (MGNX) | 2.5 | $128M | 4.6M | 27.92 | |
Phathom Pharmaceuticals (PHAT) | 2.5 | $126M | 3.8M | 32.91 | |
Arvinas Ord (ARVN) | 2.4 | $123M | 3.7M | 33.54 | |
Rhythm Pharmaceuticals (RYTM) | 2.3 | $116M | 5.2M | 22.30 | |
Kala Pharmaceuticals | 2.2 | $114M | 11M | 10.51 | |
Black Diamond Therapeutics (BDTX) | 2.1 | $109M | 2.6M | 42.16 | |
Legend Biotech Corp Sponsored Ads (LEGN) | 2.1 | $106M | 2.5M | 42.56 | |
Eidos Therapeutics | 2.0 | $103M | 2.2M | 47.67 | |
Alector (ALEC) | 2.0 | $101M | 4.1M | 24.44 | |
Zogenix Com New | 1.9 | $99M | 3.7M | 27.01 | |
Retrophin | 1.8 | $95M | 4.6M | 20.41 | |
Momenta Pharmaceuticals | 1.6 | $84M | 2.5M | 33.27 | |
Wave Life Sciences SHS (WVE) | 1.6 | $81M | 7.8M | 10.41 | |
Igm Biosciences (IGMS) | 1.4 | $72M | 983k | 73.00 | |
Keros Therapeutics (KROS) | 1.4 | $70M | 1.9M | 37.51 | |
Geron Corporation (GERN) | 1.3 | $66M | 30M | 2.18 | |
89bio (ETNB) | 1.2 | $63M | 3.2M | 19.93 | |
Akouos | 1.0 | $51M | 2.3M | 22.50 | |
Trillium Therapeutics Com New | 1.0 | $50M | 6.2M | 8.09 | |
Orchard Therapeutics Ads | 0.9 | $46M | 10M | 4.39 | |
Ardelyx (ARDX) | 0.8 | $43M | 6.3M | 6.92 | |
Crinetics Pharmaceuticals In (CRNX) | 0.8 | $41M | 2.3M | 17.52 | |
Relmada Therapeutics (RLMD) | 0.7 | $38M | 852k | 44.75 | |
Prevail Therapeutics Ord | 0.7 | $37M | 2.5M | 14.90 | |
Arcutis Biotherapeutics (ARQT) | 0.7 | $35M | 1.2M | 30.24 | |
Stoke Therapeutics (STOK) | 0.5 | $27M | 1.1M | 23.83 | |
Scpharmaceuticals (SCPH) | 0.5 | $26M | 3.5M | 7.36 | |
Avadel Pharmaceuticals Sponsored Adr | 0.5 | $25M | 3.1M | 8.08 | |
Imara | 0.4 | $23M | 829k | 27.63 | |
Ocular Therapeutix (OCUL) | 0.4 | $23M | 2.7M | 8.33 | |
Larimar Therapeutics (LRMR) | 0.4 | $20M | 1.5M | 12.85 | |
Concert Pharmaceuticals I equity | 0.4 | $19M | 1.9M | 9.95 | |
Verastem | 0.3 | $16M | 9.1M | 1.72 | |
Syndax Pharmaceuticals (SNDX) | 0.3 | $15M | 1.0M | 14.82 | |
Celldex Therapeutics Com New (CLDX) | 0.3 | $15M | 1.2M | 13.00 | |
Sutro Biopharma (STRO) | 0.3 | $15M | 1.9M | 7.76 | |
Solid Biosciences | 0.3 | $13M | 4.6M | 2.93 | |
Repare Therapeutics Ord (RPTX) | 0.2 | $13M | 409k | 31.02 | |
Lyra Therapeutics (LYRA) | 0.2 | $9.3M | 816k | 11.34 | |
Passage Bio (PASG) | 0.2 | $8.8M | 323k | 27.33 | |
Arya Sciences Acquisition Corp Unit 06/09/2027 | 0.2 | $8.1M | 700k | 11.60 | |
Galera Therapeutics (GRTX) | 0.1 | $5.9M | 825k | 7.14 | |
Essa Pharma Com New (EPIX) | 0.1 | $5.3M | 849k | 6.20 | |
X4 Pharmaceuticals (XFOR) | 0.1 | $5.2M | 560k | 9.32 | |
Insmed Com Par $.01 (INSM) | 0.0 | $2.4M | 87k | 27.54 | |
Ovid Therapeutics (OVID) | 0.0 | $2.1M | 285k | 7.37 | |
Selecta Biosciences | 0.0 | $270k | 95k | 2.84 |